Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method
Author
Nasa, PrashantAzoulay, Elie
Khanna, Ashish K
Jain, Ravi
Gupta, Sachin
Javeri, Yash
Juneja, Deven
Rangappa, Pradeep
Sundararajan, Krishnaswamy
Alhazzani, Waleed
Antonelli, Massimo
Arabi, Yaseen M
Bakker, Jan
Brochard, Laurent J
Deane, Adam M
Du, Bin
Einav, Sharon
Esteban, Andrés
Gajic, Ognjen
Galvagno, Samuel M
Guérin, Claude
Jaber, Samir
Khilnani, Gopi C
Koh, Younsuck
Lascarrou, Jean-Baptiste
Machado, Flavia R
Malbrain, Manu L N G
Mancebo, Jordi
McCurdy, Michael T
McGrath, Brendan A
Mehta, Sangeeta
Mekontso-Dessap, Armand
Mer, Mervyn
Nurok, Michael
Park, Pauline K
Pelosi, Paolo
Peter, John V
Phua, Jason
Pilcher, David V
Piquilloud, Lise
Schellongowski, Peter
Schultz, Marcus J
Shankar-Hari, Manu
Singh, Suveer
Sorbello, Massimiliano
Tiruvoipati, Ravindranath
Udy, Andrew A
Welte, Tobias
Myatra, Sheila N
Date
2021-03-16Journal
Critical care (London, England)Publisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
Using a Delphi process, an international panel of 39 experts developed clinical practice statements on the respiratory management of C-ARF in areas where evidence is absent or limited. Agreement was defined as achieved when > 70% experts voted for a given option on the Likert scale statement or > 80% voted for a particular option in multiple-choice questions. Stability was assessed between the two concluding rounds for each statement, using the non-parametric Chi-square (χ2) test (p < 0·05 was considered as unstable).Keyword
COVID 19 invasive mechanical ventilationCOVID-19 acute respiratory distress syndrome
COVID-19 high flow nasal oxygen
COVID-19 respiratory management
COVID-19 ventilatory management
Respiratory distress syndrome adult
Identifier to cite or link to this item
http://hdl.handle.net/10713/15104ae974a485f413a2113503eed53cd6c53
10.1186/s13054-021-03491-y
Scopus Count
Related articles
- [Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].
- Authors: Pfeifer M, Ewig S, Voshaar T, Randerath W, Bauer T, Geiseler J, Dellweg D, Westhoff M, Windisch W, Schönhofer B, Kluge S, Lepper PM
- Issue date: 2020 Jun
- Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
- Authors: Dioh W, Chabane M, Tourette C, Azbekyan A, Morelot-Panzini C, Hajjar LA, Lins M, Nair GB, Whitehouse T, Mariani J, Latil M, Camelo S, Lafont R, Dilda PJ, Veillet S, Agus S
- Issue date: 2021 Jan 11
- ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs.
- Authors: Chawla R, Dixit SB, Zirpe KG, Chaudhry D, Khilnani GC, Mehta Y, Khatib KI, Jagiasi BG, Chanchalani G, Mishra RC, Samavedam S, Govil D, Gupta S, Prayag S, Ramasubban S, Dobariya J, Marwah V, Sehgal I, Jog SA, Kulkarni AP
- Issue date: 2020 Jan
- Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
- Authors: Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J
- Issue date: 2020 Oct 28
- Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.
- Authors: Pfeifer M, Ewig S, Voshaar T, Randerath WJ, Bauer T, Geiseler J, Dellweg D, Westhoff M, Windisch W, Schönhofer B, Kluge S, Lepper PM
- Issue date: 2020
Related items
Showing items related by title, author, creator and subject.
-
Immune Correlates of COVID-19 ControlPoonia, Bhawna; Kottilil, Shyam (Frontiers Media S.A., 2020-09-29)COVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effective immunity in most individuals along with high infectiousness of the virus has resulted in massive global public health emergency. Intense efforts are on to study viral pathogenesis and immune response to help guide prophylactic and therapeutic interventions as well as epidemiological assessments like transmission modeling. To develop an effective vaccine or biologic therapeutic, it is critical to understand the immune correlates of COVID-19 control. At the same time, whether immunity in recovered individuals is effective for preventing re-infection will be important for informing interventions like social distancing. Key questions that are being investigated regarding immune response in COVID-19 which will help these efforts include, investigations of immune response that distinguishes patients with severe versus mild infection or those that recover relative to those that succumb, durability of immunity in recovered patients and relevance of developed immunity in a cured patient for protection against re-infection as well as value of convalescent plasma from recovered patients as a potential therapeutic modality. This is a broad and rapidly evolving area and multiple reports on status of innate and adaptive immunity against SARS-CoV2 are emerging on a daily basis. While many questions remain unanswered for now, the purpose of this focused review is to summarize the current understanding regarding immune correlates of COVID-19 severity and resolution in order to assist researchers in the field to pursue new directions in prevention and control. © Copyright © 2020 Poonia and Kottilil.
-
Tell Us Why You Got the COVID-19 VaccineWilson, Paulette (2021-02-02)
-
Tell Us Why You Got the COVID-19 Vaccine: Rosie LoveMorrison, Joanne (2021-02-24)